Mixed-Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis

J Viral Hepat. 2024 Nov;31(11):775-779. doi: 10.1111/jvh.13995. Epub 2024 Aug 12.

Abstract

The prevalence of mixed hepatitis C virus (HCV) genotype infection in a representative Canadian HCV cohort is reported and virological response with direct acting antiviral (DAA) treatment was evaluated. 3272 HCV-positive participants were enrolled, of which 2945 (90.0%) initiated DAA therapy. 0.8% were identified with mixed genotype infection. Overall sustained virological response (SVR) was 99.1% and did not differ based on mixed genotype status. Any historical disadvantage to achieving cure with HCV treatment in mixed genotype infection has been overcome by current DAA regimens.

Keywords: direct acting antivirals; hepatitis C; mixed genotypes; outcomes.

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents* / pharmacology
  • Antiviral Agents* / therapeutic use
  • Canada / epidemiology
  • Cohort Studies
  • Coinfection / drug therapy
  • Coinfection / virology
  • Female
  • Genotype*
  • Hepacivirus* / classification
  • Hepacivirus* / drug effects
  • Hepacivirus* / genetics
  • Hepatitis C, Chronic* / drug therapy
  • Hepatitis C, Chronic* / virology
  • Humans
  • Male
  • Middle Aged
  • Prevalence
  • Sustained Virologic Response*
  • Treatment Outcome

Substances

  • Antiviral Agents